Search

Displaying results 6711 - 6720 of 10000 in total
  1. Drug

    Rocapuldencel-T

    go.drugbank.com/drugs/DB17588
    Investigational

    Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

  2. Drug

    Amedalin

    go.drugbank.com/drugs/DB09188
    Experimental

    Amedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. … It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.

  3. Drug

    Tetramisole

    go.drugbank.com/drugs/DB16561
    Investigational

    Tetramisole is an anthelmintic agent.[A275223]

  4. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

    Synonyms: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea
  5. Drug

    Lexanersen

    go.drugbank.com/drugs/DB17933
    Investigational

    Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.

  6. Drug

    Zifibancimig

    go.drugbank.com/drugs/DB19332
    Investigational

    Zifibancimig is under investigation in clinical trial NCT04567303, focusing on participants with neovascular age-related macular degeneration.

  7. Drug

    Dynorphin

    go.drugbank.com/drugs/DB16146
    Investigational

    Dynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).

  8. Drug

    C-peptide

    go.drugbank.com/drugs/DB16187
    Investigational

    C-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy).

  9. Drug

    Evobrutinib

    go.drugbank.com/drugs/DB15170
    Investigational

    Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).

  10. Drug

    Tranilast

    go.drugbank.com/drugs/DB07615
    Investigational

    Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

    Synonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acid